Business
The BARD1 (ASX:BD1) share price eyes record highs after positive research results
The BARD1 Life Sciences (ASX: BD1) share price is on watch today after positive results from the evaluation of its EXO-NET product in pancreatic cancer.
Let’s take a closer look at the announcement and what this means for the BARD1 share price.
What’s driving the BARD1 share price higher?
BARD1 maintains a cancer diagnostics portfolio. This includes the commercialised hTRET test which is used as a supplement to urine cytology tests. Additionally, the portfolio also includes diagnostics tests in development for ovarian, breast, lung, prostate, and pancreatic cancers. The group is working towards commercialising its…
-
General19 hours agoFour escape injury after jumping from three-storey unit on fire in Newcastle
-
Noosa News18 hours agoGippsland vegetable farm accused of underpaying migrant workers
-
General16 hours agoIncreased police powers begin at Adelaide Oval Ashes Test following Bondi attacks
-
General23 hours agoDe-escalation skills, not guards, needed in Tasmanian hospitals, nurses’ union says